Trial Profile
The efficacy and safety for T2DM patients with OAD losing efficacy receiving insulin aspart 30 plus metformin compared with insulin aspart 30 monotherapy
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 28 Apr 2016
Price :
$35
*
At a glance
- Drugs Insulin aspart/insulin protamine aspart (Primary) ; Metformin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 28 Apr 2016 New trial record